The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
about
Cancer Evolution and the Limits of Predictability in Precision Cancer MedicineAcute myeloid leukaemia: a paradigm for the clonal evolution of cancer?Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticlesMDR1 causes resistance to the antitumour drug miltefosineModeling Tumor Clonal Evolution for Drug Combinations DesignEvolution of acquired resistance to anti-cancer therapy.Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.What does physics have to do with cancer?Mutation and epigenetic molecular clocks in cancer.Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effectsClinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential.Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancerImpact of obesity on chemotherapy management and outcomes in women with gynecologic malignanciesIn vivo uptake of 131I-5-iodo-2-deoxyuridine by malignant tumours in manHistological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancerCancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?Mechanisms of resistance to combinations of vincristine, etoposide and doxorubicin in Chinese hamster ovary cells.Weight-based chemotherapy dosing in obese patients with cancer: back to the future.The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.The mesenchymal tumor microenvironment: a drug-resistant niche.In vivo emergence of a highly metastatic tumour cell line from a rat rhabdomyosarcoma after treatment with an alkylating agent.Thermochemotherapy-induced resistance to cyclophosphamide.Tumour response to chemotherapy in animals that have been treated with the same drugs prior to tumour implantation: a model for studying host effects on apparent drug resistance.Cross resistance pattern towards anticancer drugs of a human carcinoma multidrug-resistant cell line.Sensitivity of locally recurrent rat mammary tumour cell lines to syngeneic polymorphonuclear cell, macrophage and natural killer cell cytolysis.Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative GroupInferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancersA phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605).Clonal evolution of acute myeloid leukemia highlighted by latest genome sequencing studies.Addressing genetic tumor heterogeneity through computationally predictive combination therapy.How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.Molecular tumor clocks to study the evolution of drug resistance.A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity.Evolutionary scalpels for dissecting tumor ecosystems.Therapy's Shadow: A Short History of the Study of Resistance to Cancer Chemotherapy.A theoretical quantitative model for evolution of cancer chemotherapy resistanceAmplicon structure in multidrug-resistant murine cells: a nonrearranged region of genomic DNA corresponding to large circular DNA.Intraperitoneal cytostatics impair early post-operative collagen synthesis in experimental intestinal anastomosesP6Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin.Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias
P2860
Q26767415-9D769FC0-109B-4AB1-BAE8-9C2899DE5A54Q26828997-207236BB-82C6-46C6-90BE-3F5C13CB3D00Q27026080-6E1589B5-1915-43C5-BA7D-27039FB0BF47Q28365282-14E48003-FBC6-43F7-90E4-31B4DCB8632AQ33590430-29E75DC8-0D26-4E04-9784-112D862D85E6Q33758382-03E5460E-D3BA-4760-BAE0-A27845B53159Q33917455-21F951FF-9BDC-4143-BE62-AD1746CD53D9Q34208808-A07D7819-625E-4F7B-B076-1508F938BE7AQ34520423-437F5144-42E4-4ABF-9801-056650294D62Q34691351-FDC968EF-64C8-4FFD-AF99-FA6557E6E6BDQ35021459-DBE47308-C8EC-4D9E-BB7D-60BAED9922C4Q35591358-F430AA3D-C1DA-49DB-BF14-3A16B27C259EQ35748477-61219055-0AEC-4318-AF03-ED3D1777F0C7Q35982556-49686388-AFDE-4C2E-B4C3-13BD0E03849BQ36027935-E1ACFB14-A204-49A5-AE69-B2EC1AAD001CQ36037500-2146C059-D4E2-4818-B835-DD9489B289B9Q36080575-6E66D228-F3DE-438B-B437-5340B5ECB9EAQ36095287-19440BB1-48D5-4121-A2A3-0923BC700B76Q36172312-042F3EA1-8436-46CE-A997-A600517452A3Q36187755-A2C8A63C-3554-4991-ACC1-686910755EB0Q36465785-B64656B7-A83F-4811-A0FC-3DF1E5BB24D3Q36466117-7AD70DE6-7487-4CF2-A348-2CF9B011D67FQ36466628-C692DA49-CC98-4567-AA79-CE3386FABA8BQ36466678-CC8D5B3A-3401-4DBD-B197-2E12D47E6DB7Q36466811-BADE2D62-9A2B-4391-8CCF-608FFB5E4ACCQ36678707-535B428E-F8ED-48E0-9D8F-1E21A760CA41Q37117418-A9457443-908F-4EF4-9670-FA0568BD2533Q37424044-D9F163E3-B66F-4A9D-8569-B7AD13D48A06Q37629073-AFF62981-0D19-4FF0-A19B-C4D71AE4D16DQ37683771-395684DC-E7DD-4AAB-8805-89F5299EDD63Q37793837-DFA0E571-4636-48B2-8734-B5FB7F433621Q37898098-EF73F284-BB44-45FD-87F0-E6AAF741D2B6Q38843089-B5D54205-05F6-4B18-A643-AA09C8D859ACQ39030938-1CEF18AE-77A0-42F7-A18D-66E5073DD73AQ40462770-D4DC9AD3-9942-4450-9076-11F7A7803801Q40516956-234A3A9C-3282-4056-8463-28CEF89372E2Q40678220-4DF9FE15-FCA9-466D-9AD8-96766E79D991Q41118633-AE8F28CC-2B6E-405A-80C0-73D371B7E7EDQ41146888-25093A9A-0D58-4FA8-82E3-59D72B09F51AQ41606250-A8C0DF5C-B673-4A18-BE67-8DD1267D433C
P2860
The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh-hant
name
The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
@en
The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
@nl
type
label
The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
@en
The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
@nl
prefLabel
The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
@en
The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
@nl
P1433
P1476
The genetic origin of drug resistance in neoplasms: implications for systemic therapy
@en
P2093
P304
P407
P577
1984-09-01T00:00:00Z